catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
Company profile
Ticker
GYRE
Exchange
Website
CEO
Nassim Usman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CATALYST BIOSCIENCES, INC., TARGACEPT INC
SEC CIK
Corporate docs
Subsidiaries
Further Challenger International Limited • Nepenthe Holdings Limited • Ratel Holdings Limited • Aaring Limited • Rosefinch Holdings Limited • Continent Pharmaceuticals Inc. • BJContinent Pharmaceuticals Limited • Beijing Continent Pharmaceuticals Co., Ltd. • Beijing Continent Biomedical Technology Co., Ltd. ...
IRS number
562020050
GYRE stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Mar 24
8-K
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
25 Mar 24
8-K
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 Mar 24
8-K
Results of Operations and Financial Condition
14 Feb 24
8-K/A
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K/A
Completion of Acquisition or Disposition of Assets
12 Jan 24
8-K
Departure of Directors or Certain Officers
15 Dec 23
Transcripts
Latest ownership filings
144
Notice of proposed sale of securities
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
NASSIM USMAN
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Rodney L Nussbaum
21 Mar 24
3
Rodney L Nussbaum
21 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.23 mm | 2.23 mm | 2.23 mm | 2.23 mm | 2.23 mm | 2.23 mm |
Cash burn (monthly) | 1.57 mm | 1.74 mm | 541.00 k | 3.68 mm | 1.07 mm | 1.11 mm |
Cash used (since last report) | 10.71 mm | 11.90 mm | 3.70 mm | 25.19 mm | 7.34 mm | 7.63 mm |
Cash remaining | -8.48 mm | -9.67 mm | -1.47 mm | -22.96 mm | -5.11 mm | -5.40 mm |
Runway (months of cash) | -5.4 | -5.6 | -2.7 | -6.2 | -4.8 | -4.8 |
Institutional ownership, Q3 2023
12.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 6 |
Closed positions | 3 |
Increased positions | 7 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 685.73 mm |
Total shares | 10.83 mm |
Total puts | 0.00 |
Total calls | 14.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GNI | 6.27 mm | $0.00 |
Singer Julian D. | 1.08 mm | $563.00 k |
Integrated Core Strategies | 683.93 k | $4.32 mm |
JFL Capital Management | 640.31 k | $6.34 mm |
Renaissance Technologies | 590.69 k | $285.00 k |
Geode Capital Management | 258.75 k | $124.82 mm |
Vanguard | 206.90 k | $99.79 mm |
BLK Blackrock | 153.76 k | $74.16 mm |
MS Morgan Stanley | 97.75 k | $47.14 mm |
Kynam Capital Management | 90.06 k | $43.44 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Usman Nassim | Common Stock | Sell | Dispose S | No | Yes | 16.15 | 20,000 | 323.00 k | 1,636 |
1 Apr 24 | Usman Nassim | Common Stock | Option exercise | Acquire M | No | No | 6.93 | 20,000 | 138.60 k | 21,636 |
1 Apr 24 | Usman Nassim | Stock Option Common Stock | Option exercise | Dispose M | No | No | 6.93 | 20,000 | 138.60 k | 301,652 |
20 Mar 24 | Rodney L Nussbaum | Stock Option Common Stock | Grant | Acquire A | No | No | 17.86 | 1,866 | 33.33 k | 1,866 |
15 Mar 24 | Usman Nassim | Common Stock | Sell | Dispose S | No | Yes | 17.26 | 20,000 | 345.20 k | 1,636 |
15 Mar 24 | Usman Nassim | Common Stock | Option exercise | Acquire M | No | No | 6.93 | 20,000 | 138.60 k | 21,636 |
15 Mar 24 | Usman Nassim | Stock Option Common Stock | Option exercise | Dispose M | No | No | 6.93 | 20,000 | 138.60 k | 321,652 |
20 Nov 23 | Charles C Wu | Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 170,417 | 127.81 k | 170,417 |
News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
11 Apr 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
12 Health Care Stocks Moving In Thursday's Intraday Session
29 Feb 24
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
23 Feb 24